CN1387439A - 糖尿肾病和微蛋白尿的治疗方法 - Google Patents

糖尿肾病和微蛋白尿的治疗方法 Download PDF

Info

Publication number
CN1387439A
CN1387439A CN00815232A CN00815232A CN1387439A CN 1387439 A CN1387439 A CN 1387439A CN 00815232 A CN00815232 A CN 00815232A CN 00815232 A CN00815232 A CN 00815232A CN 1387439 A CN1387439 A CN 1387439A
Authority
CN
China
Prior art keywords
diabetic
level
danshen
urine
chinese herbal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00815232A
Other languages
English (en)
Chinese (zh)
Inventor
李海日
李勋哲
郑万吉
苏德海·V·沙赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiva Biomedical LLC
Original Assignee
Shiva Biomedical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiva Biomedical LLC filed Critical Shiva Biomedical LLC
Publication of CN1387439A publication Critical patent/CN1387439A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN00815232A 1999-09-29 2000-09-21 糖尿肾病和微蛋白尿的治疗方法 Pending CN1387439A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/408,436 1999-09-29
US09/408,436 US6149915A (en) 1999-09-29 1999-09-29 Treatment of diabetic nephropathy and microalbuminuria

Publications (1)

Publication Number Publication Date
CN1387439A true CN1387439A (zh) 2002-12-25

Family

ID=23616291

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00815232A Pending CN1387439A (zh) 1999-09-29 2000-09-21 糖尿肾病和微蛋白尿的治疗方法

Country Status (7)

Country Link
US (3) US6149915A (https=)
EP (1) EP1218020A1 (https=)
JP (1) JP2003510286A (https=)
CN (1) CN1387439A (https=)
AU (1) AU771275B2 (https=)
CA (1) CA2386000A1 (https=)
WO (1) WO2001022981A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311413A (zh) * 2015-11-18 2016-02-10 暨南大学 治疗糖尿病肾病的含有艾叶的中药组合物及其制备方法
CN110215449A (zh) * 2019-05-13 2019-09-10 中国科学院长春应用化学研究所 紫草酸在抑制胰岛素淀粉样多肽聚集中的应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149915A (en) * 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
DE10229180A1 (de) 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
EP1706108A4 (en) * 2003-12-30 2009-08-12 Md Bioalpha Co Ltd TREATMENT OF FAT AND METABOLIC SYNDROME WITH TRANSHINONE DERIVATIVES FOR INCREASING METABOLISM ACTIVITY
WO2006082643A1 (ja) 2005-02-03 2006-08-10 Taiyo Kagaku Co., Ltd. 糖尿病および／または糖尿病性腎症の予防、改善、または治療用組成物
CN100341581C (zh) * 2005-07-29 2007-10-10 上海第二医科大学附属第九人民医院 一种丹酚酸b有效干预口腔癌动物模型的方法
US20070027209A1 (en) * 2005-08-01 2007-02-01 Lee Hyun C Prevention and treatment of atherosclerosis with lithospermate B
JP5169818B2 (ja) * 2006-03-07 2013-03-27 日本新薬株式会社 育毛剤
WO2008117901A1 (en) 2007-03-28 2008-10-02 Industry-Academic Cooperation Foundation, Yonsei University A method for isolation of high concentration of magnesium lithospermate b from salviae miltiorrhizae
US9345732B2 (en) 2009-11-19 2016-05-24 Laila Nutraceuticals Agents derived from Holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases
CN102550916A (zh) * 2012-02-04 2012-07-11 王姗思 一种用于糖尿病肾病的食品
CN102614267A (zh) * 2012-04-24 2012-08-01 许风国 一种治疗糖尿病肾病的中药组合物及其制备方法
CN103830496A (zh) * 2014-02-28 2014-06-04 廊坊市思科农业技术有限公司 一种辅助降糖的组合物
CN104974119B (zh) * 2014-04-01 2018-10-19 中国科学院上海药物研究所 一种高纯度丹酚酸b镁及其制备方法
CN104547498A (zh) * 2014-12-31 2015-04-29 黎细乐 一种中药组合物的新用途
US20160361288A1 (en) * 2015-06-10 2016-12-15 Postech Academy-Industry Foundation Pharmaceutical compositions for preventing or treating diabetic nephropathy comprising the activity inhibitor of tenc1
CN107551172A (zh) * 2017-10-26 2018-01-09 马雪英 一种治疗肾病综合症的药物及其制备方法
CN112190646B (zh) * 2020-11-19 2021-12-28 首都医科大学附属北京中医医院 一种治疗糖尿病肾病的中药组合物及其制备方法
CN112569313B (zh) * 2020-12-28 2022-02-22 贵州三力制药股份有限公司 治疗肾病的中药组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01268682A (ja) * 1988-04-21 1989-10-26 Minofuaagen Seiyaku Honpo:Goushi 腎機能改善剤及びリソスペルミン酸塩の製造方法
US5358962A (en) * 1993-04-22 1994-10-25 Minophagen Pharmaceutical Company Antihypertensive method
JP3638967B2 (ja) * 1993-06-03 2005-04-13 日本ケミカルリサーチ株式会社 ネフローゼ症候群及び肝障害症状の寛解剤
JP3161882B2 (ja) * 1993-06-03 2001-04-25 日本ケミカルリサーチ株式会社 丹参由来多糖類、その製造法および用途
US5547945A (en) * 1993-07-15 1996-08-20 Jcr Pharmaceuticals Co., Ltd. Remitting agent for nephrotic syndrome and hepatopathy symptoms
US6149915A (en) * 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311413A (zh) * 2015-11-18 2016-02-10 暨南大学 治疗糖尿病肾病的含有艾叶的中药组合物及其制备方法
CN110215449A (zh) * 2019-05-13 2019-09-10 中国科学院长春应用化学研究所 紫草酸在抑制胰岛素淀粉样多肽聚集中的应用

Also Published As

Publication number Publication date
AU771275B2 (en) 2004-03-18
CA2386000A1 (en) 2001-04-05
US20020025347A1 (en) 2002-02-28
EP1218020A1 (en) 2002-07-03
WO2001022981A1 (en) 2001-04-05
AU4023501A (en) 2001-04-30
US6267992B1 (en) 2001-07-31
US6149915A (en) 2000-11-21
JP2003510286A (ja) 2003-03-18

Similar Documents

Publication Publication Date Title
CN1387439A (zh) 糖尿肾病和微蛋白尿的治疗方法
KR101031605B1 (ko) 당뇨병 질환의 예방 및 치료를 위한 세리포리아 락세라타 배양액 추출물의 제조방법 및 이에 따른 세리포리아 락세라타 배양액 추출물
Ishak et al. Antidiabetic and hypolipidemic activities of Curculigo latifolia fruit: root extract in high fat fed diet and low dose STZ induced diabetic rats
AU2016246524A1 (en) Pharmaceutical compositions for combination therapy
Zhang et al. Tangduqing granules attenuate insulin resistance and abnormal lipid metabolism through the coordinated regulation of PPARγ and DGAT2 in type 2 diabetic rats
CN106310146B (zh) 具有防治慢性肾衰功效的中药组合物及其制备方法与应用
Baek et al. Antihyperglycemic and Antilipidemic Effects of the Ethanol Extract Mixture of Ligularia fischeri and Momordica charantia in Type II Diabetes‐Mimicking Mice
CN102861201B (zh) 一种治疗糖尿病的药物组合物及其制备方法
Cao et al. Egg white-derived peptides reduced blood glucose in high-fat-diet and low-dose streptozotocin-induced type 2 diabetic mice via regulating the hepatic gluconeogenic signaling and metabolic profile
Wen et al. Alleviating effect of mulberry leaf 1-deoxynojirimycin on resistin-induced hepatic steatosis and insulin resistance in mice
CA3022247C (en) Composition for treating diabetic disease
CN114569613A (zh) 蝙蝠葛生物碱类化合物在治疗代谢性疾病中的应用
CN101829271B (zh) 一种具有治疗糖尿病作用的中药复方及其制备方法和应用
CN102631358A (zh) 虎杖苷在制备糖尿病肾病治疗药物中的应用
CN110314160B (zh) 小檗胺在制备预防和治疗糖尿病肾病药物中的应用
CN113244208A (zh) Hpa在制备治疗非酒精性脂肪性肝病药物中的应用
WO2014086255A1 (zh) 山药多糖和山药蛋白质的组合物的用途
CN1221258C (zh) 苄达赖氨酸在制备预防和治疗糖尿病肾病药物中的应用
Liu et al. Effects of dexmedetomidine on the degree of myocardial ischemia-reperfusion injury, oxidative stress and TLR4/NF-κB signaling pathway in rats.
CN100336526C (zh) 一种治疗糖尿病的药物组合物及其制备方法
Hu et al. Hypoglycemic effects and mechanisms of animal-derived blood peptides in C2C12 myotubes and alloxan-induced diabetic mice
Akpotu et al. Modulatory Effect of Fraction of Dryopteris dilatata on Alloxan-induced Oxidative Stress, Hepato-nephro Injury in Wistar Rat Models
Ali et al. Modulation of Glycemic, Lipid, and HepatorenalBiomarkers by Silymarin Supplementation inType 2 Diabetes Mellitus
Xiu-wen et al. The effect of characteristic Li-medicine Alpinia officinarum Hance on improving insulin resistance.
Jin et al. The inhibition of megalin-mediated transcytosis of thyroglobulin as a mechanism for insulin resistance-induced hypothyroidism in male rats

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication